Phytosome in Rheumatoid Arthritis Management: A Comprehensive Review

Rheumatoid arthritis (RA) leads to joint deterioration and inflammation, causing pain and disability. Traditional therapies like Non-steroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs), and biological products have limitations and adverse effects, prompting interest in complementary treatments like phytosomes. Phytosomes enhance the bioavailability of plant-derived chemicals by combining them with phospholipids. Substances like curcumin, boswellic acids and EGCG exhibit anti-inflammatory and antioxidant properties relevant to RA. Phytosomal formulations of these compounds show increased effectiveness compared to conventional forms. Curcumin and boswellic acids in phytosomal form demonstrate anti-inflammatory and cartilage-protective benefits in RA models. Epigallocatechin-3-gallate (EGCG) from green tea, when phytosomally delivered, reduces inflammatory mediator release and aids in joint tissue healing. Moreover, phytosomal formulations may reduce systemic toxicity associated with traditional RA treatments, crucial for managing the disease's chronic nature. Phytosomes may modulate the immune system, impacting cytokine production and immune cell activity, potentially modifying the disease course. Despite promising preclinical and some clinical data, further randomized controlled studies are needed to confirm the safety and efficacy of phytosomal treatments for RA. Personalized treatment regimens and evaluation of herb-drug interactions are vital considerations. Hence, phytosomes offer improved bioavailability and therapeutic potential for plant-derived compounds in RA therapy. However, a comprehensive understanding of their mechanisms, dosage optimization, and long-term safety necessitates further research. Integrating phytosomes into RA care could provide patients with additional options for symptom relief and enhanced quality of life.